global
spread
requir
urgent
need
find
effect
therapeut
treatment
develop
datadriven
drug
reposit
framework
appli
machin
learn
statist
analysi
approach
systemat
integr
mine
largescal
knowledg
graph
literatur
transcriptom
data
discov
potenti
drug
candid
retrospect
studi
use
past
sarscov
merscov
data
demonstr
machin
learn
base
method
success
predict
effect
drug
candid
biorxiv
preprint
specif
coronaviru
silico
screen
follow
wetlab
valid
indic
polyadpribos
polymeras
inhibitor
current
phase
clinic
trial
may
repurpos
treat
vitro
assay
reveal
exhibit
effect
inhibitori
activ
replic
without
obviou
cytopath
effect
addit
show
abl
suppress
cpginduc
product
peripher
blood
mononuclear
cell
suggest
may
also
antiinflammatori
effect
highli
relev
prevent
immunopatholog
induc
infect
pharmacokinet
toxicokinet
evalu
rat
monkey
show
high
concentr
lung
observ
appar
sign
toxic
indic
appeal
potenti
drug
treatment
pneumonia
caus
infect
moreov
molecular
dock
simul
suggest
may
bind
ntermin
domain
nucleocapsid
n
protein
provid
possibl
model
explain
antivir
action
also
propos
sever
possibl
mechan
explain
antivir
activ
inhibitor
base
data
present
studi
previou
evid
report
literatur
summari
inhibitor
discov
datadriven
drug
reposit
framework
serv
potenti
therapeut
agent
treatment
authorfund
right
reserv
reus
allow
without
permiss
biorxiv
preprint
known
evid
report
literatur
also
discuss
sever
put
mechan
effect
inhibitor
involv
treatment
overal
result
indic
inhibitor
identifi
drug
reposit
pipelin
may
serv
effect
therapeut
agent
result
overview
datadriven
drug
reposit
framework
shown
figur
first
construct
viru
relat
knowledg
graph
consist
drugtarget
interact
proteinprotein
interact
similar
network
public
avail
databas
method
three
differ
type
node
ie
drug
human
target
viru
target
within
knowledg
graph
connect
edg
describ
interact
associ
similar
establish
bridg
inform
aggreg
knowledg
mine
appli
networkbas
knowledg
mine
algorithm
predict
initi
list
drug
candid
potenti
use
treat
infect
figur
method
next
narrow
list
drug
candid
previous
report
evid
antivir
activ
base
text
mine
result
largescal
literatur
text
deriv
deep
learn
base
relat
extract
method
name
bere
figur
method
follow
minimum
manual
check
use
connect
map
analysi
approach
gene
express
profil
ten
sarscovinfect
patient
refin
list
drug
candid
figur
tabl
tabl
method
screen
process
reveal
polyadpribos
polymeras
inhibitor
could
potenti
antivir
activ
authorfund
right
reserv
reus
allow
without
permiss
outbreak
pneumonia
name
caus
novel
coronaviru
infect
peopl
worldwid
march
apart
china
countri
region
includ
south
korea
iran
europ
report
rapid
increas
number
case
impli
novel
coronaviru
pose
global
health
threat
current
circumst
absenc
specif
vaccin
medicin
urgent
discov
effect
therapi
especi
drug
treat
result
diseas
prevent
viru
spread
consid
develop
new
drug
gener
take
year
probabl
best
therapeut
shortcut
appli
drug
reposit
strategi
ie
find
new
use
old
drug
identifi
potenti
antivir
effect
exist
drug
approv
clinic
use
enter
clinic
trial
exist
drug
potent
antivir
efficaci
directli
appli
treat
short
time
safeti
verifi
principl
clinic
trial
studi
appli
datadriven
framework
combin
machin
learn
statist
analysi
method
systemat
integr
largescal
avail
coronavirusrel
data
identifi
drug
candid
set
drug
candid
mainli
includ
approv
investig
experiment
drug
silico
screen
process
follow
experiment
valid
reveal
polyadpribos
polymeras
inhibitor
current
phase
clinic
trial
may
serv
potenti
drug
candid
treat
vitro
assay
demonstr
exhibit
effect
inhibitori
activ
replic
dosedepend
manner
obviou
cytopath
effect
addit
found
human
peripher
blood
mononuclear
cell
pbmc
abl
suppress
cpginduc
product
report
previous
high
relev
viral
pathogenesi
especi
intens
care
unit
icu
patient
infect
vivo
pharmacokinet
toxicokinet
studi
rat
monkey
show
highli
distribut
lung
tissu
appar
sign
toxic
observ
make
appeal
potenti
drug
candid
treatment
novel
pneumonia
caus
infect
moreov
molecular
dock
studi
suggest
may
bind
ntermin
domain
nucleocapsid
n
protein
provid
possibl
mode
antivir
action
base
data
present
studi
previou
demonstr
comput
pipelin
drug
reposit
yield
reason
accur
predict
result
also
valid
networkbas
knowledg
mine
algorithm
figur
use
retrospect
data
two
coronavirus
close
relat
rel
well
studi
literatur
ie
sarscov
merscov
aid
develop
text
mine
tool
bere
found
mani
drug
report
previous
literatur
antivir
activ
correspond
coronaviru
also
among
top
list
predict
result
tabl
exampl
chloroquin
fdaapprov
drug
treat
malaria
previous
report
exhibit
micromolar
antisarscov
activ
vitro
also
repurpos
target
viru
predict
framework
gemcitabin
origin
approv
treat
certain
type
cancer
also
predict
target
sarscov
valid
previou
vitro
studi
cyclosporin
calcineurin
inhibitor
approv
immunomodulatori
drug
observ
block
replic
sarscov
also
success
predict
approach
among
predict
top
list
merscov
miltefosin
approv
treat
leishmaniasi
previous
identifi
antimerscov
activ
chlorpromazin
imatinib
use
treat
schizophrenia
leukemia
respect
also
select
comput
pipelin
antimerscov
drug
valid
previou
vitro
experi
thu
retrospect
studi
illustr
comput
framework
abl
predict
effect
drug
candid
specif
coronaviru
still
current
preclin
trial
stage
drugbank
id
select
two
inhibitor
includ
olaparib
mefuparib
hydrochlorid
figur
current
fdaapprov
phase
clinic
trial
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
respect
initi
studi
first
conduct
pilot
experiment
test
vitro
method
activ
olaparib
sever
relat
drug
figur
found
inhibitor
olaparib
exhibit
inhibitori
effect
replic
nevertheless
show
much
higher
inhibit
rate
olaparib
specif
olaparib
inhibit
replic
concentr
reach
reduct
concentr
notabl
antivir
efficaci
even
surpass
arbidol
one
standard
treatment
diagnosi
treatment
protocol
novel
coronaviru
pneumonia
trial
version
promulg
chines
govern
http
particular
arbidol
inhibit
replic
much
lower
concentr
figur
contrast
oseltamivir
zanamivir
drug
use
prevent
influenza
viru
infect
baricitinib
inhibitor
recommend
treat
show
inhibitori
activ
concentr
base
pilot
experiment
result
chose
subsequ
experiment
studi
vitro
assay
method
show
exhibit
effect
inhibitori
activ
replic
dosedepend
manner
ec
figur
also
assess
cytotox
assay
method
found
cc
systemat
assess
inhibitori
activ
also
perform
timeofaddit
assay
method
determin
stage
inhibit
viral
infect
remdesivir
enter
clinic
trial
treatment
http
also
test
assay
comparison
particular
compar
dmso
control
group
remdesivir
show
potent
antivir
activ
fulltim
procedur
infect
vero
cell
figur
result
timeofaddit
assay
indic
partial
work
viral
entri
significantli
inhibit
replic
viru
postentri
remdesivir
function
postentri
stage
figur
togeth
result
vitro
assay
indic
evalu
potenti
therapeut
agent
treat
recent
becom
evid
one
import
cytokin
viral
infect
emerg
clinic
studi
human
anim
link
excess
synthesi
persist
mani
virus
human
immunodefici
viru
hiv
foot
mouth
diseas
viru
vesicular
stomat
viru
vsv
addit
vivo
studi
friend
retroviru
fv
mous
model
show
blockag
reduc
viral
load
enhanc
virusspecif
tcell
immun
find
support
hypothesi
rapid
product
might
possibl
mechan
lead
deleteri
clinic
manifest
viral
pathogenesi
recent
publish
research
clinic
characterist
sever
patient
infect
show
significantli
elev
especi
icu
patient
caus
excess
activ
immun
respons
patholog
role
infect
indic
blockad
may
provid
feasibl
therapi
treatment
test
whether
abl
regul
product
vitro
stimul
product
peripher
blood
mononuclear
cell
pmbc
cpgodn
effect
stimul
cytokin
chemokin
incub
pbmc
cpgodn
h
method
induc
product
compar
untreat
cell
figur
presenc
stimulatori
effect
cpgodn
counteract
studi
show
inhibit
cpginduc
upregul
timeand
dosedepend
manner
figur
specif
exposur
concentr
h
attenu
cpginduc
product
respect
result
provid
vitro
evid
support
potenti
therapeut
agent
treat
proinflammatori
respons
caus
infect
possess
good
pharmacokinet
toxicokinet
characterist
anim
highest
tissu
distribut
lung
rat
perform
vivo
pharmacokinet
toxicokinet
evalu
anim
method
first
examin
concentr
differ
tissu
rat
differ
time
point
post
oral
administr
differ
dose
figur
tabl
also
previous
report
among
seven
tissu
ie
lung
spleen
liver
kidney
stomach
heart
brain
observ
lung
highest
concentr
higher
compar
plasma
tabl
observ
lung
highest
concentr
line
fact
viru
patholog
impact
lung
high
viral
load
suggest
potenti
use
indic
lung
lesion
caus
infect
antivir
profil
establish
anim
model
clinic
trial
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
furthermor
compar
pharmacokinet
data
arbidol
broadspectrum
antivir
drug
commerci
china
sinc
recommend
treat
patient
chines
govern
found
pharmacokinet
paramet
arbidol
compar
similar
plasma
concentr
drug
exposur
tabl
arbidol
mostli
distribut
stomach
plasma
post
administr
rat
contrast
higher
distribut
tissu
especi
lung
rather
plasma
compar
arbidol
indic
superior
pharmacokinet
profil
may
render
better
potenti
antivir
treatment
infect
lung
rat
oral
administr
mgkg
consecut
day
follow
day
without
drug
administr
method
observ
signific
differ
bodi
weight
rat
among
differ
dosag
control
group
figur
next
conduct
toxicokinet
analysi
rat
method
particular
rat
given
mgkg
oral
gavag
day
consecut
day
follow
day
without
administr
investig
revers
toxic
effect
compound
examin
whether
potenti
delayedonset
toxic
drug
rat
result
show
maximum
toler
dose
mtd
noobserv
advers
effect
level
noael
mgkg
mgkg
respect
exposur
femal
rat
auc
day
day
male
rat
auc
day
day
tabl
base
toxicokinet
result
repeat
dose
studi
rat
surviv
treatment
period
show
appar
sign
toxic
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
monkey
administ
mgkg
nasogastr
feed
tube
consecut
daili
dose
schedul
day
follow
recoveri
period
method
slight
decreas
bodi
weight
observ
highdos
mgkg
group
chang
revers
recoveri
period
overal
vivo
data
show
possess
good
pharmacokinet
toxicokinet
characterist
rat
monkey
highlevel
distribut
therapeut
target
tissu
ie
lung
may
greatli
favor
treatment
infect
previou
studi
report
inhibitor
target
ntermin
domain
ntd
coronaviru
nucleocapsid
n
protein
reduc
rna
bind
thu
imped
viral
replic
specul
olaparib
may
also
interact
n
protein
perform
similar
antivir
function
test
hypothesi
conduct
molecular
dock
studi
potenti
interact
two
drug
nntd
method
overal
structur
anoth
coronaviru
phylogenet
close
relat
share
similar
composit
secondari
structur
element
includ
five
conserv
strand
flexibl
loop
figur
addit
sequenc
cover
correspond
bind
pocket
region
well
conserv
figur
thu
structur
may
provid
common
molecular
featur
term
interact
small
molecul
bind
pocket
therefor
also
use
experiment
solv
structur
complex
refer
analyz
dock
result
dock
result
detail
also
found
supplementari
studi
report
top
data
integr
approach
combin
machin
learn
statist
analysi
techniqu
follow
weblab
experiment
valid
identifi
potenti
drug
candid
treat
infect
show
inhibitor
discov
silico
drug
repurpos
framework
may
therapeut
potenti
treatment
although
mainli
conduct
vitro
assay
experiment
valid
effect
olaparib
due
limit
time
natur
specul
inhibitor
may
also
antivir
activ
infect
base
comput
predict
experiment
valid
result
base
data
present
studi
previous
known
evid
report
literatur
propos
sever
potenti
mechan
help
understand
involv
inhibitor
treatment
figur
first
life
cycl
coronaviru
inhibitor
may
inhibit
viral
growth
suppress
viral
replic
imped
bind
nucleocapsid
protein
viral
rna
also
support
molecular
dock
result
see
section
second
inhibitor
previous
report
play
critic
role
regul
inflammatori
respons
modul
express
proinflammatori
factor
downstream
cytokin
chemokin
also
shown
overactiv
promot
energi
nad
atp
consumpt
drive
cell
death
exacerb
inflamm
respons
inhibitor
thu
may
repress
proinflammatori
signal
reduc
energi
failur
subsequ
cell
death
induc
necrosi
thu
provid
clinic
potenti
attenu
cytokin
storm
inflammatori
respons
caus
infect
third
adpribosyl
conserv
posttransl
modif
nucleocapsid
protein
across
differ
coronaviru
lineag
impli
may
import
regulatori
role
structur
pack
viral
genom
sever
previou
studi
demonstr
critic
viral
replic
exampl
report
interact
hemagglutinin
ha
influenza
viru
iav
promot
replic
trigger
degrad
host
type
ifn
receptor
addit
adpribosyl
adenovir
core
protein
display
antivir
defens
mechan
therefor
interven
adpribosyl
mediat
interplay
viral
protein
may
anoth
import
pathway
inhibitor
prevent
infect
cours
throughli
understand
role
inhibitor
experiment
studi
direct
clinic
evid
need
futur
consid
proinflammatori
role
therapeut
effect
inhibitor
inflammatorymedi
diseas
extens
studi
past
two
decad
earli
gener
inhibitor
suggest
previou
studi
neuroprotect
effect
stroke
model
protect
mice
necroptosisassoci
liver
injuri
repress
express
addit
fdaapprov
inhibitor
olaparib
report
protect
lp
lipopolysaccharid
induc
acut
lung
kidney
injuri
manner
mice
numer
preclin
studi
demonstr
inhibitor
play
essenti
role
rang
inflammatori
injuri
relat
diseas
especi
lung
inflammatori
disord
includ
ard
acut
respiratori
distress
syndrom
copd
chronic
obstruct
pulmonari
diseas
asthma
studi
suggest
inhibitor
high
relev
treatment
novel
pneumonia
caus
infect
possibl
via
role
modul
inflammatori
respons
notabl
current
patholog
studi
shown
sever
patient
infect
gener
higher
plasma
level
impli
high
risk
inflammatoryassoci
cytokin
storm
viral
infect
addit
reduct
function
exhaust
cell
also
observ
patient
therefor
block
overact
inflammatori
respons
may
effect
strategi
treatment
particularli
icu
patient
infect
recent
tocilizumab
monoclon
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
bodi
drug
target
recommend
treatment
diagnosi
treatment
protocol
novel
coronaviru
pneumonia
trial
version
promulg
chines
govern
http
also
highlight
vital
role
antiinflammatori
respons
current
therapeut
vitro
studi
show
effect
inhibit
product
induc
cpg
pbmc
figur
find
indic
may
also
possess
specif
antiinflammatori
effect
applic
sever
patient
infect
inhibitor
origin
use
target
homolog
recombin
repair
defect
cancer
mainli
categor
oncolog
drug
thu
would
gener
need
safeti
data
justifi
repurpos
inhibitor
nononcolog
indic
fortun
numer
exist
preclin
clinic
studi
repurpos
inhibitor
nononcolog
diseas
includ
aforement
acut
diseas
eg
acut
respiratori
distress
syndrom
ard
stroke
chronic
diseas
eg
rheumatoid
arthriti
vascular
diseas
evid
indic
possibl
repurpos
inhibitor
safe
therapeut
agent
treat
current
acut
lung
diseas
caus
infect
addit
pharmacokinet
toxicokinet
data
rat
monkey
shown
studi
indic
may
rel
accept
safeti
profil
reposit
antivir
purpos
moreov
approv
enter
phase
clinic
trial
nation
medic
product
administr
nmpa
china
cancer
treatment
preliminari
data
phase
clinic
trial
shown
well
toler
ascend
dose
studi
dose
high
mg
qd
mg
bid
grade
ii
advers
event
observ
indic
also
quit
safe
well
toler
human
pharmacokinet
examin
rat
shown
highest
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
level
distribut
lung
tissu
higher
concentr
compar
plasma
tissu
specif
enrich
lung
may
bring
extra
advantag
use
purpos
lung
therapeut
target
tissu
moreov
high
level
distribut
lung
may
also
suggest
low
dosag
need
order
ensur
therapeut
efficaci
may
reduc
risk
advers
event
thu
may
great
potenti
repurpos
effect
therapeut
agent
combat
prevent
futur
epidem
outbreak
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
method
virusrel
knowledg
graph
construct
predict
coronaviru
relat
drug
total
seven
network
consid
construct
knowledg
graph
figur
includ
human
targetdrug
interact
network
viru
targetdrug
interact
network
human
proteinprotein
interact
network
viru
proteinhuman
protein
interact
network
drug
molecular
similar
network
human
protein
sequenc
similar
network
viru
protein
sequenc
similar
network
human
targetdrug
interact
network
deriv
drugbank
version
viru
targetdrug
interact
network
construct
integr
data
drugbank
version
chembl
releas
ttd
last
updat
nov
iuphar
bp
releas
nov
bindinddb
ghddi
http
vcovexperimentdata
cutoff
threshold
ic
ec
k
k
human
proteinprotein
interact
network
viru
proteinhuman
protein
interact
network
construct
integr
data
biogrid
releas
huri
instruct
mint
updat
pina
signalink
innatedb
drug
molecular
similar
network
obtain
calcul
tanimoto
similar
morgan
fingerprint
radiu
comput
use
rdkit
tool
protein
sequenc
similar
network
human
viru
obtain
calcul
smithwaterman
similar
amino
acid
sequenc
deriv
uniprot
use
sequenc
align
softwar
provid
note
collect
addit
protein
sequenc
uniprot
ad
correspond
network
final
predict
drug
without
drugtarget
interact
outsid
drugbank
databas
remov
correspond
network
construct
virusrel
knowledg
graph
merg
togeth
node
edg
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
seven
network
figur
construct
knowledg
graph
g
v
e
undirect
graph
node
v
v
node
set
v
belong
one
node
type
includ
drug
human
protein
viru
protein
edg
e
e
edg
set
e
v
v
r
belong
one
relat
type
relat
type
set
r
includ
two
drugtarget
interact
two
proteinprotein
interact
three
similar
initi
list
drug
candid
target
first
screen
use
networkbas
knowledg
mine
algorithm
modifi
previou
work
goal
captur
hidden
virusrel
featur
inform
accur
predict
potenti
drug
candid
construct
knowledg
graph
realiz
learn
network
topologypreserv
embed
node
specif
model
use
graph
convolut
algorithm
gather
updat
featur
inform
node
construct
heterogen
knowledg
graph
network
neighborhood
network
topolog
inform
fulli
exploit
suppos
perform
iter
graph
convolut
iter
messag
v
pass
node
v
express
v
u
r
stand
weight
edg
e
u
v
r
u
v
r
av
u
r
u
av
u
r
w
r
r
featur
h
v
node
v
updat
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
w
r
b
r
stand
learnabl
paramet
concat
stand
concaten
oper
final
confid
score
u
v
relat
r
node
u
node
v
deriv
learn
node
embed
correspond
project
matric
g
r
h
r
r
stand
edgetyp
specif
project
matric
minim
bayesian
person
rank
bpr
loss
drugtarget
interact
reconstruct
regard
edg
edg
set
e
miss
valu
rather
neg
sampl
u
v
w
x
stand
confid
score
relat
r
u
v
w
x
respect
stand
sigmoid
activ
function
intuit
loss
function
confid
score
node
pair
u
v
edg
set
ie
u
v
r
e
encourag
higher
unseen
pair
w
x
ie
w
x
r
e
predict
confid
score
relat
viru
targetdrug
interact
viru
targetdrug
pair
use
equat
confid
score
averag
across
protein
certain
viru
eg
sarscov
merscov
correspond
pvalu
obtain
ztest
viru
select
predict
pvalu
drug
candid
use
deep
learn
base
relat
extract
method
name
bere
extract
coronaviru
relat
drug
largescal
literatur
text
specif
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
sentenc
mention
two
entiti
interest
ie
name
alia
coronaviru
coronaviru
target
name
alia
drug
first
collect
use
dictionarybas
name
entiti
recognit
method
string
match
pair
entiti
e
e
usual
one
sentenc
describ
underli
relat
therefor
use
bag
sentenc
e
e
denot
set
sentenc
mention
e
e
predict
relat
two
entiti
first
encod
sentenc
e
e
semant
syntact
manner
use
hybrid
deep
neural
network
h
r
includ
selfattent
modul
bidirect
gate
recurr
unit
gru
modul
gumbel
treegru
modul
sentenc
represent
h
score
sentencelevel
attent
modul
indic
contribut
relat
predict
r
stand
weight
score
w
r
stand
learnabl
weight
paramet
final
relat
predict
binari
classifi
base
weight
sum
sentenc
represent
r
e
e
classifi
r
e
e
stand
probabl
relat
interest
entiti
e
e
mention
bag
sentenc
e
e
train
corpu
use
curat
automat
nearli
million
pubm
http
wwwpubmedgov
abstract
distant
supervis
techniqu
detail
name
alias
drug
target
sentenc
first
annot
dictionarybas
name
entiti
recognit
method
string
match
name
dictionari
deriv
drugbank
version
ambigu
name
eg
common
word
remov
next
label
bag
sentenc
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
mention
drugtarget
pair
interest
annot
automat
known
drugtarget
interact
drugbank
unlabel
corpu
use
work
textmin
coronaviru
relat
drug
obtain
approxim
million
pmc
fulltext
articl
entiti
interest
annot
use
aforement
name
entiti
recognit
approach
coronaviru
relat
drug
extract
hit
candid
model
found
bag
sentenc
describ
relat
drug
target
coronaviru
interest
use
transcriptom
analysi
approach
filter
potenti
drug
candid
treat
patient
infect
due
lack
gene
express
data
infect
patient
use
sarscov
infect
patient
screen
potenti
therapeut
drug
candid
strategi
reason
sarscov
two
close
relat
highli
similar
coronaviru
first
genom
phylogenet
close
sarscov
sequenc
ident
membran
n
nucleocapsid
e
envelop
protein
two
coronavirus
sequenc
similar
addit
pathogen
mechan
sarscov
highli
similar
particularli
collect
gene
express
profil
peripher
blood
mononuclear
cell
pbmc
ten
sarscov
infect
patient
geo
raw
gene
express
valu
first
convert
logarithm
scale
differenti
express
valu
zscore
comput
compar
healthi
person
use
protocol
describ
mad
x
healthi
median
x
healthi
median
x
healthi
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
z
infect
stand
zscore
sarscov
infect
patient
x
infect
x
healthi
stand
gene
express
valu
logarithm
scale
infect
healthi
person
respect
median
stand
median
oper
mad
stand
median
absolut
deviat
oper
c
constant
normal
pvalu
gene
measur
express
valu
analysi
also
comput
base
zscore
upand
downregul
gene
identifi
use
cutoff
threshold
pvalu
use
connect
map
cmap
contain
cellular
gene
express
profil
perturb
well
annot
refer
compound
measur
associ
gene
express
pattern
sarscov
infect
patient
refer
compoundperturb
cell
connect
map
score
comput
base
upand
downregul
gene
set
sarscov
infect
patient
use
web
tool
http
clueioqueri
hypothesi
gene
express
pattern
result
perturb
therapeut
compound
neg
correl
result
coronaviru
infect
select
compound
signific
neg
connect
map
score
list
drug
candid
predict
treat
coronaviru
infect
patient
obtain
select
compound
connect
map
score
suggest
origin
paper
african
green
monkey
kidney
vero
cell
line
purchas
cell
resourc
center
shanghai
institut
life
scienc
chines
academi
scienc
potenti
antivir
drug
includ
zanamivir
oseltamivir
remdesivir
baricitinib
olaparib
arbidol
provid
mce
medchem
express
china
inhibitor
mefuparib
hydrochlorid
puriti
provid
convalif
shanghai
china
cytotox
test
drug
vero
cell
determin
assay
beyotim
china
h
post
addit
test
drug
ad
well
incub
c
h
optic
densiti
measur
nm
cytotox
concentr
cc
valu
calcul
use
graphpad
prism
graphpad
softwar
usa
vero
cell
seed
plate
densiti
cellswel
incub
dmem
medium
supplement
fb
h
incub
co
c
cell
reach
confluent
cell
cultur
medium
well
remov
pb
use
wash
cell
evalu
antivir
efficaci
drug
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
cultur
fresh
drugcontain
medium
c
co
atmospher
h
cultur
supernat
per
well
harvest
inactiv
c
min
extract
quantifi
viral
rna
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
treatment
test
drug
ad
cell
h
viru
infect
cell
maintain
drugviru
mixtur
h
viru
infect
process
cultur
medium
contain
viru
test
drug
replac
fresh
cultur
medium
till
end
experi
postentri
experi
viru
first
ad
cell
allow
infect
h
viruscontain
supernat
replac
drugcontain
medium
end
experi
h
post
infect
viral
inhibit
cell
supernat
test
drug
quantifi
qrtpcr
calcul
use
dmso
group
refer
vero
cell
treat
respect
follow
procedur
fulltim
treatment
infect
cell
fix
aceton
pb
permeabil
triton
block
bsa
pb
buffer
contain
tween
room
temperatur
min
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
secondari
antibodi
respect
protein
band
detect
chemiluminesc
use
ecl
kit
sangon
biotech
china
peripher
blood
mononuclear
cell
yicon
china
cultur
c
concentr
co
atmospher
plate
cell
growth
medium
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
weight
examin
serum
ml
collect
analyz
toxicokinet
differ
time
point
post
drug
administr
plasma
concentrationtim
data
analyz
use
noncompartment
method
phoenix
version
usa
deriv
pharmacokinet
paramet
thirti
spraguedawley
rat
randomli
divid
three
time
point
group
administr
anim
sacrif
brain
heart
lung
liver
spleen
stomach
kidney
tissu
collect
tissu
sampl
wash
icecold
salin
blot
paper
towel
remov
excess
fluid
weigh
tissu
sampl
fluid
weight
store
c
determin
drug
concentr
lcmsm
healthi
male
femal
cynomolgu
monkey
age
year
purchas
guangdong
landau
biotechnolog
china
anim
maintain
accord
guid
care
use
laboratori
anim
cynomolgu
monkey
select
use
computer
random
procedur
administ
nasogastr
feed
dose
level
control
mgkg
individu
dose
volum
adjust
weekli
base
bodi
weight
monkey
monkey
observ
twice
daili
viabilitymort
chang
behavior
reaction
treatment
illhealth
electrocardiogram
intraocular
pressur
rectal
temperatur
bodi
weight
record
group
anim
randomli
select
euthan
day
remain
anim
euthan
drug
free
period
blood
sampl
taken
h
postdos
day
treatment
period
pharmacokinet
evalu
perform
use
noncompartment
method
phoenix
version
usa
pharmacokinet
paramet
calcul
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
individu
monkey
data
repres
mean
standard
deviat
sd
n
valu
n
correspond
number
data
point
use
figur
prepar
use
graphpad
prism
graphpad
softwar
usa
statist
signific
calcul
spss
two
valu
consid
significantli
differ
pvalu
dock
program
use
model
molecular
interact
inhibitor
olaparib
ntermin
domain
n
protein
structur
use
molecular
dock
built
homolog
model
autogrid
program
use
gener
grid
map
point
space
equal
evalu
bind
energi
protein
ligand
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
connect
map
filter
antisarscov
drug
candid
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
figur
effect
bodi
weight
rat
monkey
b
rat
monkey
oral
administ
mgkg
mgkg
respect
consecut
day
follow
day
without
drug
administr
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
second
possibl
pathway
prevent
overactiv
thu
avoid
deplet
nad
atp
consequ
cellular
energi
failur
cell
death
caus
necrosi
c
potenti
antivir
effect
inhibitor
suppress
adpribosyl
viral
protein
interven
hostpathogen
interact
thu
result
inhibit
viral
replic
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
tabl
top
list
drug
candid
identifi
connect
map
analysi
use
gene
express
profil
peripher
blood
mononuclear
cell
pbmc
sampl
ten
sarscovinfect
patient
connect
map
score
use
cutoff
threshold
determin
top
list
ie
drug
candid
connect
score
queri
rank
top
refer
perturb
select
two
inhibitor
ie
veriparib
chosen
top
list
shown
bold
bind
surfac
olaparib
similar
exactli
two
carbonyl
group
olaparib
form
hydrogen
bond
residu
distanc
respect
addit
residu
around
bind
surfac
ie
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
particip
interact
olaparib
via
hydrophob
interact
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
figur
structur
inhibitor
mention
studi
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
tabl
toxicokinet
paramet
rat
fourweek
toxic
studi
n
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
